Revolutionizing Sickle Cell Disease Treatment: Unveiling CRISPR and Lentiviral Therapies—Navigating Complexities in Access, Equity, and Global Health Dynamics.
Advancing Sickle Cell Disease Treatment: Addressing Access Challenges In this editorial, we discuss the recent approval by the U.S. Food and Drug Administration (FDA) of two new treatments, Casgevy and Lyfgenia, for sickle cell disease (SCD) in patients aged 12 and older. These treatments are signif...
| Publicado en: | Plasmatology Vol. 18; pp. 1 - 3 |
|---|---|
| Autor principal: | |
| Formato: | letter Journal Article |
| Publicado: |
Sage Publications Inc.
5/20/2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |